Measurements of changes in gene activation and expression provide a basis to understand genetic changes that cause biological responses. Cell-to-cell gene disruption induced by Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) technology and other gene-perturbation technologies help tease out the drivers of these responses. Adaptations of these two screening approaches can be used to discover the genetic drivers responsible for phenotypic variabilities such as drug sensitivities and disease variation across tissue microenvironments and between single cells.
Join this webinar to get an overview of recent publications illustrating the successful use of functional CRISPR screening and other related methods.
Paul Diehl, PhD, Chief Operating Officer, Cellecta, Inc.
Dr. Paul Diehl joined Cellecta, Inc. in July 2010 where he applies over two decades of experience in biotechnology to developing and expanding the company’s commercial and collaborative activities. Prior to joining Cellecta, Dr. Diehl held various marketing and business development positions at B-Bridge International, Agilent Technologies, Clontech Laboratories and other companies. Dr. Diehl received his BA in Biology from LaSalle University in Philadelphia, PA and his PhD in Biochemistry from Washington State University in Pullman, WA.Message Presenter
Who Should Attend?
This webinar will appeal to:
- Principal investigators (PI’s)
- Research Scientists
- Chief Science Officers
- Research Directors
- Post-doctoral Researchers
- Research Associates
- Directors of Research & Development
What You Will Learn
Get an overview of recent peer-reviewed publications demonstrating how functional CRISPR screening and other related methods have been used to identify:
- genes modulating drug response
- genes responsible for drug resistance
- possible mechanisms of action of drugs
Cellecta is a trusted provider of functional genomic products and services with over 15 years of experience working with the world’s leading pharma, biotech, and academic institutions. Our portfolio includes products and services for loss-of-function and gain-of-function phenotypic screening, cell barcoding and gene expression profiling. This includes design and manufacture of custom and genome-wide CRISPR and RNAi libraries, lentiviral constructs and cell engineering services. We also offer expression profiling assays and spatial transcriptomic services for drug target and biomarker discovery and other applications.